Video

VIDEO: Once-yearly skin cancer screening might not be enough after organ transplants


 

AT THE AAD ANNUAL MEETING

References

SAN FRANCISCO – Older white men are most at risk to die from skin cancer after organ transplants, especially if they’ve had a heart or lung transplant, according to a review of more than a half million U.S. organ transplants from 1987-2013.

It’s long been known that skin cancer is far more likely after solid organ transplants, but it hasn’t been clear until now who’s most likely to die from the disease.

Overall, there were 985 skin cancer deaths following transplant, or 32 deaths per 100,000 patient-years. For white men over 50 years old with thoracic transplants, however, there were 183 deaths per 100,000 patient-years. In contrast, the age-adjusted death rate from malignant melanoma in the general population is 2.7 per 100,000 patient-years.

Investigator Dr. Sarah Arron, associate professor of dermatology at the University of California, San Francisco, explained what to do about the findings in an interview at the annual meeting of the American Academy of Dermatology.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

aotto@frontlinemedcom.com

Recommended Reading

More people die from thin melanomas than thick melanomas
MDedge Hematology and Oncology
HPV vaccine rates perpetuate racial and geographic cancer disparities
MDedge Hematology and Oncology
Skin cancer treatment costs skyrocket over past decade
MDedge Hematology and Oncology
New law will speed sunscreen ingredient approval
MDedge Hematology and Oncology
MEK inhibitors can induce skin eruptions with distinctive duskiness
MDedge Hematology and Oncology
FDA panel backs antifungal for invasive aspergillosis, mucormycosis
MDedge Hematology and Oncology
Melanoma incidence highest in Oregon, lowest in Texas in 2015
MDedge Hematology and Oncology
VIDEO: Biologics slowly taming metastatic melanoma
MDedge Hematology and Oncology
VIDEO: As biosimilars arrive in U.S., treatment questions arise
MDedge Hematology and Oncology
New 9-valent HPV vaccine shown to be as effective as quadrivalent vaccine
MDedge Hematology and Oncology